$ARVN
Arvinas Inc Stock $arvn

$arvn Overview Financials Valuation SEC Filings Company Website

2023 Q3 Form 10-Q Financial Statement

#000165575923000079 Filed on August 08, 2023

Income Statement

Concept	2023 Q3	2023 Q2
Revenue	$34.60M	$54.50M
YoY Change	14.19%	74.12%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$22.60M	$25.70M
YoY Change	13.0%	5.76%
% of Gross Profit
Research & Development	$85.90M	$103.4M
YoY Change	10.84%	37.32%
% of Gross Profit
Depreciation & Amortization	$1.200M	$1.200M
YoY Change	-25.0%	-20.0%
% of Gross Profit
Operating Expenses	$108.5M	$129.1M
YoY Change	11.28%	29.62%
Operating Profit	-$73.90M	-$74.60M
YoY Change	9.97%	9.22%
Interest Expense	$0.00	$0.00
YoY Change	-100.0%	-100.0%
% of Operating Profit
Other Income/Expense, Net	$10.00M	$9.000M
YoY Change	212.5%	429.41%
Pretax Income	-$63.90M	-$65.60M
YoY Change	-0.16%	-1.5%
Income Tax	$0.00	-$300.0K
% Of Pretax Income
Net Earnings	-$64.00M	-$66.60M
YoY Change	-3.32%	-4.86%
Net Earnings / Revenue	-184.97%	-122.2%
Basic Earnings Per Share	-$1.18	-$1.25
Diluted Earnings Per Share	-$1.18	-$1.25
COMMON SHARES
Basic Shares Outstanding	53.49M shares	53.40M shares
Diluted Shares Outstanding	54.10M shares	53.40M shares

Balance Sheet

Concept	2023 Q3	2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$998.5M	$1.039B
YoY Change	-21.42%	-22.66%
Cash & Equivalents	$113.7M	$90.60M
Short-Term Investments	$884.8M	$948.2M
Other Short-Term Assets	$13.90M	$13.10M
YoY Change	-48.9%	-47.81%
Inventory
Prepaid Expenses
Receivables	$15.70M	$100.0K
Other Receivables	$4.900M	$4.700M
Total Short-Term Assets	$1.033B	$1.057B
YoY Change	-20.82%	-23.23%
LONG-TERM ASSETS
Property, Plant & Equipment	$12.70M	$13.20M
YoY Change	-9.29%	-2.94%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$9.600M	$10.10M
YoY Change	-15.04%	-13.68%
Total Long-Term Assets	$25.30M	$26.80M
YoY Change	-15.95%	-12.42%
TOTAL ASSETS
Total Short-Term Assets	$1.033B	$1.057B
Total Long-Term Assets	$25.30M	$26.80M
Total Assets	$1.058B	$1.084B
YoY Change	-20.71%	-22.99%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$34.30M	$6.700M
YoY Change	334.18%	-45.53%
Accrued Expenses	$57.50M	$69.00M
YoY Change	3094.44%	119.05%
Deferred Revenue	$224.2M	$230.1M
YoY Change	16.11%	18.36%
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$200.0K	$100.0K
YoY Change
Total Short-Term Liabilities	$317.3M	$306.9M
YoY Change	29.72%	28.84%
LONG-TERM LIABILITIES
Long-Term Debt	$800.0K	$900.0K
YoY Change	-20.0%	-10.0%
Other Long-Term Liabilities	$283.0M	$312.1M
YoY Change	-39.49%	-37.23%
Total Long-Term Liabilities	$800.0K	$900.0K
YoY Change	-20.0%	-10.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$317.3M	$306.9M
Total Long-Term Liabilities	$800.0K	$900.0K
Total Liabilities	$601.1M	$619.9M
YoY Change	-15.73%	-15.82%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.178B	-$1.114B
YoY Change	33.47%	36.46%
Common Stock	$100.0K	$100.0K
YoY Change	0.0%	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$457.2M	$463.6M
YoY Change
Total Liabilities & Shareholders Equity	$1.058B	$1.084B
YoY Change	-20.71%	-22.99%

Cashflow Statement

Concept	2023 Q3	2023 Q2
OPERATING ACTIVITIES
Net Income	-$64.00M	-$66.60M
YoY Change	-3.32%	-4.86%
Depreciation, Depletion And Amortization	$1.200M	$1.200M
YoY Change	-25.0%	-20.0%
Cash From Operating Activities	-$84.80M	-$88.70M
YoY Change	27.33%	12.85%
INVESTING ACTIVITIES
Capital Expenditures	$1.100M	$600.0K
YoY Change	-150.0%	-142.86%
Acquisitions
YoY Change
Other Investing Activities	$71.10M	$49.20M
YoY Change	-34.17%	-55.43%
Cash From Investing Activities	$70.00M	$48.60M
YoY Change	-33.84%	-55.41%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	37.90M	500.0K
YoY Change	3058.33%	0.0%
NET CHANGE
Cash From Operating Activities	-84.80M	-88.70M
Cash From Investing Activities	70.00M	48.60M
Cash From Financing Activities	37.90M	500.0K
Net Change In Cash	23.10M	-39.60M
YoY Change	-42.82%	-228.16%
FREE CASH FLOW
Cash From Operating Activities	-$84.80M	-$88.70M
Capital Expenditures	$1.100M	$600.0K
Free Cash Flow	-$85.90M	-$89.30M
YoY Change	33.39%	15.67%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q2	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1 RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1	P6M
CY2023Q2	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1 RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1	P1Y
CY2023Q2	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1 RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1	P1Y
CY2023Q2	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1 RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1	P1Y
CY2023Q2	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1 RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1	P1Y
CY2023Q2	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1 RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1	P1Y
CY2023Q2	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1 RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
CY2023Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	53400000	shares
CY2023Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	53400000	shares
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.32
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.32
CY2023Q2	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	500000	usd
CY2023Q2	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	400000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	463600000	usd
	arvn	Proceeds From Exercise Of Stock Options And Issuance Of Employee Stock Shares ProceedsFromExerciseOfStockOptionsAndIssuanceOfEmployeeStockShares	3000000.0	usd
CY2022Q2	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-3300000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	564900000	usd
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	38200000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-148500000	usd
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	2000000.0	usd
	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	7000000.0	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	463600000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	781700000	usd
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	36600000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-133400000	usd
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	3100000	usd
	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-17400000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	670600000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-148500000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-133400000	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	2400000	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	3000000.0	usd
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	7000000.0	usd
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-5800000	usd
	us-gaap	Debt Securities Available For Sale Gain Loss DebtSecuritiesAvailableForSaleGainLoss	-900000	usd
	us-gaap	Debt Securities Available For Sale Gain Loss DebtSecuritiesAvailableForSaleGainLoss	-100000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	900000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	1000000.0	usd
	us-gaap	Capitalized Contract Cost Amortization CapitalizedContractCostAmortization	1500000	usd
	us-gaap	Capitalized Contract Cost Amortization CapitalizedContractCostAmortization	800000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	38200000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	36600000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-900000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-13600000	usd
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	-2400000	usd
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	-4000000.0	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-13100000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1000000.0	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-600000	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-12700000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-1000000.0	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-1000000.0	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-83100000	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-52500000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-179900000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-135700000	usd
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	492300000	usd
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	469100000	usd
	arvn	Proceeds From Maturities Of Marketable Securities ProceedsFromMaturitiesOfMarketableSecurities	638900000	usd
	arvn	Proceeds From Maturities Of Marketable Securities ProceedsFromMaturitiesOfMarketableSecurities	555900000	usd
	arvn	Proceeds From Sale Of Marketable Securities ProceedsFromSaleOfMarketableSecurities	34300000	usd
	arvn	Proceeds From Exercise Of Stock Options And Issuance Of Employee Stock Shares ProceedsFromExerciseOfStockOptionsAndIssuanceOfEmployeeStockShares	2000000.0	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2000000.0	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3000000.0	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	9300000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-15100000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	86800000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	112800000	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	96100000	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	97700000	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	400000	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	500000	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	9000000.0	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	usd
	us-gaap	Use Of Estimates UseOfEstimates	The preparation of the Company’s unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make certain estimates and assumptions that affect the reported amount of assets, liabilities, revenue and expenses. These estimates include assumptions and judgments based on historical experience, current conditions, future expectations and other factors the Company considers reasonable. These estimates are reviewed on an ongoing basis and revised as necessary. Actual results could differ from these estimates.
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	Risks and UncertaintiesThe Company is subject to a number of risks similar to other biotechnology companies in the early stage, including, but not limited to, the need to obtain adequate additional funding, possible failure of preclinical testing or clinical trials, the need to obtain marketing approval for its product candidates, competitors developing new technological innovations, the need to successfully commercialize and gain market acceptance of the Company’s products and protection of proprietary technology. If the Company does not successfully obtain regulatory approval, it will be unable to generate revenue from product sales or achieve profitability.
CY2023Q2	arvn	Cash Cash Equivalents Restricted Cash And Marketable Securities CashCashEquivalentsRestrictedCashAndMarketableSecurities	1000000000	usd
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	90600000	usd
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	93200000	usd
CY2023Q2	us-gaap	Restricted Cash Current RestrictedCashCurrent	5500000	usd
CY2022Q2	us-gaap	Restricted Cash Current RestrictedCashCurrent	4500000	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	96100000	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	97700000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1000000.0	usd
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	15000000.0	usd
	arvn	Accounts Receivable After Allowance For Credit Loss Current Additions AccountsReceivableAfterAllowanceForCreditLossCurrentAdditions	1600000	usd
	arvn	Accounts Receivable After Allowance For Credit Loss Current Additions AccountsReceivableAfterAllowanceForCreditLossCurrentAdditions	1400000	usd
	arvn	Accounts Receivable After Allowance For Credit Loss Current Payments Received AccountsReceivableAfterAllowanceForCreditLossCurrentPaymentsReceived	2500000	usd
	arvn	Accounts Receivable After Allowance For Credit Loss Current Payments Received AccountsReceivableAfterAllowanceForCreditLossCurrentPaymentsReceived	15000000.0	usd
CY2023Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	100000	usd
CY2022Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1400000	usd
CY2022Q4	arvn	Accounts Payable Contract Balances Current AccountsPayableContractBalancesCurrent	5000000.0	usd
CY2021Q4	arvn	Accounts Payable Contract Balances Current AccountsPayableContractBalancesCurrent	0	usd
	arvn	Accounts Payable Contract Balances Current Additions AccountsPayableContractBalancesCurrentAdditions	1700000	usd
	arvn	Accounts Payable Contract Balances Current Additions AccountsPayableContractBalancesCurrentAdditions	0	usd
	arvn	Accounts Payable Contract Balances Current Payments AccountsPayableContractBalancesCurrentPayments	6700000	usd
	arvn	Accounts Payable Contract Balances Current Payments AccountsPayableContractBalancesCurrentPayments	0	usd
CY2023Q2	arvn	Accounts Payable Contract Balances Current AccountsPayableContractBalancesCurrent	0	usd
CY2022Q2	arvn	Accounts Payable Contract Balances Current AccountsPayableContractBalancesCurrent	0	usd
CY2022Q4	us-gaap	Contract With Customer Asset Net ContractWithCustomerAssetNet	10700000	usd
CY2021Q4	us-gaap	Contract With Customer Asset Net ContractWithCustomerAssetNet	12500000	usd
	arvn	Contract With Customer Assets Increase Decrease For Additions To Collaboration Agreements ContractWithCustomerAssetsIncreaseDecreaseForAdditionsToCollaborationAgreements	0	usd
	arvn	Contract With Customer Assets Increase Decrease For Additions To Collaboration Agreements ContractWithCustomerAssetsIncreaseDecreaseForAdditionsToCollaborationAgreements	0	usd
	arvn	Capitalized Contract Cost Amortization During Period CapitalizedContractCostAmortizationDuringPeriod	1500000	usd
	arvn	Capitalized Contract Cost Amortization During Period CapitalizedContractCostAmortizationDuringPeriod	800000	usd
CY2023Q2	us-gaap	Contract With Customer Asset Net ContractWithCustomerAssetNet	9200000	usd
CY2022Q2	us-gaap	Contract With Customer Asset Net ContractWithCustomerAssetNet	11700000	usd
CY2022Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	623700000	usd
CY2021Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	740500000	usd
	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	-84600000	usd
	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	-55500000	usd
	arvn	Contract With Customer Liability Increase Decrease For Additions To Collaboration Agreements ContractWithCustomerLiabilityIncreaseDecreaseForAdditionsToCollaborationAgreements	1500000	usd
	arvn	Contract With Customer Liability Increase Decrease For Additions To Collaboration Agreements ContractWithCustomerLiabilityIncreaseDecreaseForAdditionsToCollaborationAgreements	3000000.0	usd
CY2023Q2	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	540600000	usd
CY2022Q2	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	688000000.0	usd
CY2023Q2	us-gaap	Contract With Customer Liability Cumulative Catch Up Adjustment To Revenue Modification Of Contract ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract	0	usd
	us-gaap	Contract With Customer Liability Cumulative Catch Up Adjustment To Revenue Modification Of Contract ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract	-8200000	usd
	us-gaap	Contract With Customer Liability Cumulative Catch Up Adjustment To Revenue Modification Of Contract ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract	0	usd
CY2022Q2	us-gaap	Contract With Customer Liability Cumulative Catch Up Adjustment To Revenue Modification Of Contract ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract	0	usd
CY2023Q2	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	540600000	usd
CY2023Q2	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	110200000	usd
CY2023Q2	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	200900000	usd
CY2023Q2	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	90200000	usd
CY2023Q2	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	55300000	usd
CY2023Q2	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	34700000	usd
CY2023Q2	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	10800000	usd
CY2023Q2	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	38500000	usd
CY2023Q2	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	540600000	usd
CY2023Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	32000000.0	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	30000000.0	usd
CY2023Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	18800000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	16600000	usd
CY2023Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	13200000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	13400000	usd
CY2023Q2	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1200000	usd
CY2022Q2	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1500000	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	2400000	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	3000000	usd
CY2021Q2	us-gaap	Land Subject To Ground Leases LandSubjectToGroundLeases	160000	sqft
CY2021Q2	arvn	Base Lease Rent Period BaseLeaseRentPeriod	P10Y
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	5700000	usd
CY2023Q2	arvn	Accrued Research And Development Expense Current AccruedResearchAndDevelopmentExpenseCurrent	51600000	usd
CY2022Q4	arvn	Accrued Research And Development Expense Current AccruedResearchAndDevelopmentExpenseCurrent	35900000	usd
CY2023Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	12600000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	18700000	usd
CY2023Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y9M18D
CY2023Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	500000	usd
CY2022Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	500000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	1000000.0	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	1100000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	1000000.0	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	1000000.0	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	2400000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	1000000.0	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	2200000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	500000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	0	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	3700000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	200000	usd
CY2023Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	3500000	usd
CY2023Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	6700000	usd
CY2023Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	2900000	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	4100000	usd
CY2023Q2	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	1000000.0	usd
CY2022Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	10300000	usd
CY2023Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	74800000	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	74700000	usd
CY2023Q2	us-gaap	Long Term Debt Current LongTermDebtCurrent	100000	usd
CY2022Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	0	usd
CY2023Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	900000	usd
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	1000000.0	usd
CY2023Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	0	usd
CY2023Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	200000	usd
CY2023Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	200000	usd
CY2023Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	200000	usd
CY2023Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive	200000	usd
CY2023Q2	arvn	Long Term Debt Maturity Year Six LongTermDebtMaturityYearSix	200000	usd
CY2023Q2	us-gaap	Long Term Debt LongTermDebt	1000000.0	usd
CY2023Q2	us-gaap	Interest Expense InterestExpense	0	usd
CY2022Q2	us-gaap	Interest Expense InterestExpense	0	usd
	us-gaap	Interest Expense InterestExpense	0	usd
	us-gaap	Interest Expense InterestExpense	0	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	22.79
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	41.41
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	600000	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	7100000	usd
CY2023Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-300000	usd
CY2023Q2	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.004
CY2022Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	3400000	usd
CY2022Q2	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.054
CY2023Q2	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2023Q2	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.004
CY2022Q2	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2022Q2	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.054
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-700000	usd
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.004
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	7900000	usd
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.065
	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.004
	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.065
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-66600000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-70000000.0	usd
	us-gaap	Net Income Loss NetIncomeLoss	-148500000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-133400000	usd
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	53400000	shares
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	53400000	shares
CY2022Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	53200000	shares
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	53200000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	53400000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	53400000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	53100000	shares
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.25
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.25
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.32
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.32
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.78
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.78
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.51
CY2023Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	9300000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	9300000	shares
CY2022Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6800000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6800000	shares
CY2022Q2	us-gaap	Revenues Revenues	33800000	usd
	us-gaap	Revenues Revenues	60300000	usd
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-65800000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-123400000	usd
CY2022Q2	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-2500000	usd
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-4800000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-70000000.0	usd
	us-gaap	Net Income Loss NetIncomeLoss	-133400000	usd
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.32
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.32
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.51
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.51
CY2022Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-73300000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-150800000	usd
CY2023Q2	us-gaap	Loss Contingency Accrual At Carrying Value LossContingencyAccrualAtCarryingValue	10000000	usd
CY2023Q2	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023Q2	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2023Q2	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2023Q2	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false

Files In Submission

Name	View Source	Status
0001655759-23-000079-index-headers.html	Edgar Link	pending
0001655759-23-000079-index.html	Edgar Link	pending
0001655759-23-000079.txt	Edgar Link	pending
0001655759-23-000079-xbrl.zip	Edgar Link	pending
arvinassixthleaseamendme.htm	Edgar Link	pending
arvinassixthleaseamendme001.jpg	Edgar Link	pending
arvinassixthleaseamendme002.jpg	Edgar Link	pending
arvinassixthleaseamendme003.jpg	Edgar Link	pending
arvinassixthleaseamendme004.jpg	Edgar Link	pending
arvinassixthleaseamendme005.jpg	Edgar Link	pending
arvinassixthleaseamendme006.jpg	Edgar Link	pending
arvinassixthleaseamendme007.jpg	Edgar Link	pending
arvinassixthleaseamendme008.jpg	Edgar Link	pending
arvinassixthleaseamendme009.jpg	Edgar Link	pending
arvinassixthleaseamendme010.jpg	Edgar Link	pending
arvn-20230630.htm	Edgar Link	pending
arvn-20230630.xsd	Edgar Link	pending
arvn-20230630x10qex311.htm	Edgar Link	pending
arvn-20230630x10qex312.htm	Edgar Link	pending
arvn-20230630x10qex321.htm	Edgar Link	pending
arvn-20230630x10qex322.htm	Edgar Link	pending
bayer_arvinasxamendmentx.htm	Edgar Link	pending
bayer_arvinasxamendmentx001.jpg	Edgar Link	pending
bayer_arvinasxamendmentx002.jpg	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
arvn-20230630_cal.xml	Edgar Link	unprocessable
arvn-20230630_def.xml	Edgar Link	unprocessable
arvn-20230630_lab.xml	Edgar Link	unprocessable
arvn-20230630_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
arvn-20230630_htm.xml	Edgar Link	completed
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ARVN
Arvinas Inc Stock $arvn

2023 Q3 Form 10-Q Financial Statement

#000165575923000079 Filed on August 08, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ARVN Arvinas Inc Stock $arvn

2023 Q3 Form 10-Q Financial Statement

#000165575923000079 Filed on August 08, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ARVN
Arvinas Inc Stock $arvn